IMMUNITYBIO INC (IBRX) Stock News

NASDAQ:IBRX - Nasdaq - US45256X1037 - Common Stock - Currency: USD

2.44 +0.04 (+1.46%)

After market: 2.42 -0.02 (-0.82%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

IBRX Latest News, Press Relases and Analysis

All

Press Releases

3 days ago - By: The Motley Fool

IBRX Sales Soar 2,540%

4 days ago - By: Zacks Investment Research - Mentions: LFCR

ImmunityBio (IBRX) Reports Q2 Loss, Tops Revenue Estimates

4 days ago - By: ImmunityBio, Inc.

ImmunityBio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-code

8 days ago - By: Yahoo Finance

Immunitybio (IBRX) Targets $80 Million Capital Raise for Business Operations

9 days ago - By: Yahoo Finance

ImmunityBio, Inc. (IBRX) Gains UK Approval for ANKTIVA in Bladder Cancer

15 days ago - By: ImmunityBio, Inc.

ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors

15 days ago - By: ImmunityBio, Inc.

ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates

17 days ago - By: Yahoo Finance

ImmunityBio’s (IBRX) ANKTIVA Gets Approved by UK’s Medicines and Healthcare Regulatory Agency

18 days ago - By: Benzinga

LA Times Going Public? Patrick Soon-Shiong Plans Green Bay-Style Ownership To 'Democratize' 143-Year-Old Paper

a month ago - By: ImmunityBio, Inc.

UK MHRA Approves ImmunityBio’s ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

2 months ago - By: Yahoo Finance

ImmunityBio (IBRX) Attains FDA’s Expanded Access Authorization for its Cancer BioShield Platform Anchored by ANKTIVA

2 months ago - By: ImmunityBio, Inc.

ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer

2 months ago - By: Benzinga - Mentions: EGO CENX STLD AG ...

Vera Therapeutics, Applied Digital, Kymera Therapeutics And Other Big Stocks Moving Higher On Monday

2 months ago - By: ImmunityBio, Inc.

ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors

2 months ago - By: ImmunityBio, Inc.

ImmunityBio, Saudi Arabia’s Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding to Launch Cancer BioShield™ Platform in the Middle East

3 months ago - By: Zacks Investment Research - Mentions: JNJ MRK CGON

CGON Stock Rallies 27% in a Month on Bladder Cancer Study Success

3 months ago - By: Yahoo Finance - Mentions: COMM HD CAVA PDSB ...

Piper Sandler Upgrades ImmunityBio (IBRX) to Overweight, Lifts PT

3 months ago - By: Yahoo Finance - Mentions: BAC CAVA VFC TEM

BofA Reiterates a Buy Rating on Cava Group (CAVA), Lifts PT

3 months ago - By: Yahoo Finance - Mentions: TRU TCOM TXT AESI ...

Why ImmunityBio, Inc. (IBRX) Crashed Today

3 months ago - By: Yahoo Finance - Mentions: ATYR ATAI AQST

aTyr Pharma, Inc. (ATYR): Analysts See 485% Upside Potential

3 months ago - By: Yahoo Finance - Mentions: TSLA EAT COIN HOOD ...

Jim Cramer Notes ImmunityBio (IBRX) Has “Been Losing Money Forever”

3 months ago - By: Yahoo Finance - Mentions: DHI CMG F

Why ImmunityBio, Inc. (IBRX) Surged Last Week

3 months ago - By: Zacks Investment Research

ImmunityBio (IBRX) Moves to Buy: Rationale Behind the Upgrade

3 months ago - By: Zacks Investment Research - Mentions: IMTX

ImmunityBio (IBRX) Reports Q1 Loss, Tops Revenue Estimates

3 months ago - By: ImmunityBio, Inc.

ImmunityBio Reports Doubled Net Revenue and 150% Unit Growth in Q1 2025, With Continued Strong Sales Momentum in First Quarter since J-code

3 months ago - By: Zacks Investment Research - Mentions: OVID

Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

3 months ago - By: ImmunityBio, Inc.

ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency’s Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary Disease, Following an Inconsistent Refusal to File Letter on May 2, 2025

3 months ago - By: Zacks Investment Research - Mentions: PCRX

ImmunityBio (IBRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

3 months ago - By: ImmunityBio, Inc.

Unmatched Long-Term Bladder Preservation for 36 Months in over 80 percent of Responders with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC CIS and Papillary Disease Alone – Best in Disease and Best in Class with 5 Year Follow-Up